Publications by authors named "Kalmadi R Sujith"
Lancet Respir Med
October 2024
Article Synopsis
- There is a need for better second- and third-line treatments for advanced non-small-cell lung cancer (NSCLC) without driver mutations, prompting a clinical trial.
- The trial involved 559 eligible patients with NSCLC who had failed first-line treatment and tested the effectiveness of docetaxel combined with either plinabulin or a placebo.
- Results showed that the plinabulin group had a longer median overall survival (10.5 months) compared to the placebo group (9.4 months), with over 99% of patients experiencing treatment-related adverse events.
